Association of breast cancer and diabetes mellitus in Korean postmenopausal women

2020 ◽  
Author(s):  
Boram Kim ◽  
Jee Hye Han ◽  
Hee Yong Kwak ◽  
Kil Young Kwon ◽  
Junghwan Kim
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Postmenopausal Women ◽  
Benign Breast Disease ◽  
Breast Disease ◽  
University Hospital ◽  
Control Group ◽  
Breast Clinic ◽  
Cancer Group ◽  
Increased Risk

Abstract Background: Diabetes mellitus has been associated with an increased risk of breast cancer. This association is, however, controversial, and not elucidated in Asia. This study aimed to determine the association between diabetes mellitus and breast cancer risk in Korean women.Methods: This retrospective study included subjects who underwent an ultrasound-localized needle-extracted biopsy to investigate questionable breast findings at the Eulji University Hospital breast clinic in Seoul, Korea, between 2000 and 2019. The medical records of the participants were reviewed to determine their age, diabetic status, and breast pathology findings. The participants were categorized into two groups, namely, the control group, that included those with benign breast disease; and, the breast cancer group. Logistic regression analyses were performed to assess the association between diabetes and breast cancer amongst pre- and post-menopausal participants.Results: A total of 1268 participants were included in this analysis. We found that diabetes was significantly associated with an increased odds of breast cancer (odds ratio [OR] 2.24; 95% confidence interval [CI], 1.76 to 2.84). Additionally, postmenopausal participants (aged ≥ 50 years) showed increased odds for breast cancer (OR 4.32; 95% CI, 3.37 to 5.53). The association between diabetes and breast cancer was significant, after adjusting for age, in the postmenopausal group (adjusted OR [aOR] 1.60; 95% CI, 1.09 to 2.35), but was not significant in the premenopausal group (aOR 1.10; 95% CI, 0.76 to 1.60).Conclusion: Diabetes was associated with increased odds of breast cancer compared to benign breast disease in postmenopausal women in Korea.

scholarly journals Macrophagic “Crown-like Structures” Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease

2017 ◽  
Vol 11 (2) ◽  
pp. 113-119 ◽  
Author(s):  
Jodi M. Carter ◽  
Tanya L. Hoskin ◽  
M. Alvaro Pena ◽  
Rushin Brahmbhatt ◽  
Stacey J. Winham ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Benign Breast Disease ◽  
Breast Disease ◽  
Increased Risk

scholarly journals A Cohort Study of p53 Mutations and Protein Accumulation in Benign Breast Tissue and Subsequent Breast Cancer Risk

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Geoffrey C. Kabat ◽  
Rita A. Kandel ◽  
Andrew G. Glass ◽  
Joan G. Jones ◽  
Neal Olson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Confidence Intervals ◽  
Breast Tissue ◽  
Benign Breast Disease ◽  
P53 Protein ◽  
Breast Disease ◽  
Genetic Alterations ◽  
Protein Accumulation ◽  
Missense Mutations ◽  
Increased Risk

Mutations in the p53 tumor suppressor gene and accumulation of its protein in breast tissue are thought to play a role in breast carcinogenesis. However, few studies have prospectively investigated the association of p53 immunopositivity and/or p53 alterations in women with benign breast disease in relation to the subsequent risk of invasive breast cancer. We carried out a case-control study nested within a large cohort of women biopsied for benign breast disease in order to address this question. After exclusions, 491 breast cancer cases and 471 controls were available for analysis. Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI). Neither p53 immunopositivity nor genetic alterations in p53 (either missense mutations or polymorphisms) was associated with altered risk of subsequent breast cancer. However, the combination of both p53 immunopositivity and any p53 nucleotide change was associated with an approximate 5-fold nonsignificant increase in risk (adjusted OR 4.79, 95% CI 0.28–82.31) but the confidence intervals were extremely wide. Our findings raise the possibility that the combination of p53 protein accumulation and the presence of genetic alterations may identify a group at increased risk of breast cancer.

scholarly journals The Association Between Triglyceride-Glucose Index as a Marker of Insulin Resistance and the Risk of Breast Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Sonar Soni Panigoro ◽  
Noorwati Sutandyo ◽  
Fiastuti Witjaksono ◽  
Nurjati Chairani Siregar ◽  
Ramadhan Ramli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dose Response ◽  
Univariate Analysis ◽  
Control Group ◽  
Tyg Index ◽  
Cancer Group ◽  
Triglyceride Glucose Index ◽  
Increased Risk ◽  
Referral Hospitals ◽  
Breast Cancer Group

BackgroundThis study aims to evaluate the association and dose-response between triglyceride-glucose (TyG) index and breast cancer.MethodThis is a multicenter case-control study conducted in six public referral hospitals in Indonesia. Cases are individuals aged 19 years or above who were diagnosed with breast cancer within 1 year of diagnosis, based on histopathology and immunohistochemistry. Controls were recruited from corresponding hospitals. TyG index was determined by the formula: ln (fasting TG [mg/dl] × fasting glucose [mg/dl]).ResultsThere were 212 participants in the breast cancer group and 212 participants in the control group. TyG index was higher in patients with breast cancer (median 8.65 [7.38, 10.9] vs. 8.30 [7.09, 10.84], p < 0.001). When compared with TyG quartile of Q1, Q4 was associated with an OR of 2.42 (1.77, 3.31), p < 0.001, Q3 was associated with an OR of 1.53 (1.21, 1.93), p < 0.001, Q2 was associated with an OR of 1.39 (1.12, 1.73), p = 0.002 for the risk of breast cancer. The dose-response relationship was nonlinear (p < 0.001). On univariate analysis, smoking (OR 2.15 [1.44, 3.22], p < 0.001), use of contraception (1.73 [1.15, 2.60], p = 0.008), alcohol consumption (OR 2.04 [0.96, 4.35], p = 0.064), and TyG Index >8.87 (OR 3.08 [1.93, 4.93], p < 0.001) were associated with risk of breast cancer. Independently associated with increased risk of breast cancer included smoking (OR 1.93 [1.23, 3.01], p = 0.004), use of contraception (OR 1.59 [1.02, 2.48], p = 0.039), and TyG Index >8.87 (OR 2.93 [1.72, 4.98], p < 0.001)ConclusionTyG index was associated with breast cancer in a nonlinear dose-response fashion.

scholarly journals Serum Liver Proteins and 17

2019 ◽  
Author(s):  
Zahra Tahmasebi Fard ◽  
Fatemeh Rouhollah ◽  
Nahid Nafisi
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Liver Enzymes ◽  
Sex Hormone Binding Globulin ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Serum Glutamic Oxaloacetic Transaminase ◽  
Cancer Group ◽  
17Β Estradiol ◽  
The Mean

Background: Breast cancer is a hormone-dependent malignancy that is associated with estrogen and progesterone interactions. The liver is the most important organ to be affected by the metastasis of breast cancer, which causes functional impairment. Aim: We compared levels of obesity, 17β-estradiol, and secreted proteins in postmenopausal women with breast cancer but without hepatic symptoms to those in healthy postmenopausal women. Materials and Methods: We recruited 105 postmenopausal women with breast cancer but without any clinical hepatic symptoms based on a physician’s diagnosis, and 105 healthy postmenopausal women. After taking blood samples, we separated the serum and determined the levels of alanine aminotransferase (ALT), enzyme aspartate aminotransferase (AST), sex hormone-binding globulin (SHBG), and 17β-estradiol using an enzyme-linked immunosorbent assay (ELISA). The results were statistically analyzed using SPSS. Results: The mean ages of the subjects in the cancer and control groups were 60.88 ± 0.85 and 55.56 ± 0.81 years, respectively. The exception ages (p=0.002), body mass index (BMI) values (p=0.033), serum glutamic oxaloacetic transaminase (SGOT) levels/AST levels (p=3.1*10−4), serum glutamic pyruvic transaminase (SGPT) levels/ALT levels(p=0.001), SHBG levels(p=0.014), and 17β-estradiol levels(p=0.003) in the serum differed significantly between the groups. Moreover, the mean serum 17β-estradiol (E2) levels and weights were higher in the cancer group than in the control group. Nevertheless, the mean serum levels of synthetic liver enzymes (SHBG, ALT, and AST) were lower in the cancer group than in the control group. Conclusion: In general, the postmenopausal cancer patients had higher serum estrogen levels and BMIs than their healthy counterparts. Furthermore, the levels of liver enzymes apparently decreased in the cancer group, probably owing to liver malfunction.

scholarly journals Metabolic syndrome and obesity as factors of good procnostic oncology in women in post-menopause with recent diagnosis of breast cancer

Mastology ◽  
2020 ◽  
Vol 30 (Suppl 1) ◽  
Author(s):  
Andre Hideo Motoki ◽  
Daniel de Araújo Brito Buttros ◽  
Heloisa Maria de Luca Vespoli ◽  
Eduardo Carvalho Pessoa ◽  
Eliana Aguiar Petri Nahas
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Postmenopausal Women ◽  
Fat Deposition ◽  
University Hospital ◽  
Control Group ◽  
Ki 67 ◽  
Luminal B ◽  
Central Fat ◽  
Her 2

Objective: To evaluate the association between metabolic syndrome (MS), obesity, and central fat deposition with the immunohistochemical profile (IHC) of breast cancer (BC) in postmenopausal women. Methods: A comparative cross-sectional clinical study was carried out with 63 women with recent BC and MS, compared to 126 women with recent BC, without MS (control group). Inclusion criteria were: women aged 45-75 years, amenorrhea >12 months, without previous cancer treatment, attended at a University Hospital. The groups were matched for age, time since menopause, and body mass index (BMI), in the proportion of 1 case for 2 controls, according to the sample calculation of at least 186 women in their entirety. Clinical and anthropometric data were collected; tumor size and grade and the IHC profile (ER, PR, HER2, and Ki67). By IHC convention, tumors were grouped into five subtypes: Luminal A (ER+, PR+, HER-2 -, and Ki-67 <14%); Luminal B HER-2 - (ER+, PR+ or -, HER-2 -, and Ki-67≥14%); Luminal B HER-2+ (ER+, PR+ or -, HER-2+, and any Ki-67); Non-luminal HER-2 (ER-, PR-, HER2+, and any Ki-67); and Triple-negative (ER-, PR-, HER2-, and any Ki-67). Women with three or more diagnostic criteria were considered with MS: waist circumference (WC)>88 cm; TG≥150 mg/dL; HDL cholesterol<50 mg/dL; blood pressure ≥130/85 mmHg; glucose ≥100 mg/dL. For statistical analysis, the Student’s t-test, Gamma Distribution, χ2 test and logistic regression (odds ratio–OR) were used. Results: Among the participating women, the mean age, time since menopause and BMI were: 59.0±10.6 years, 11.4±9.6 years, and 28.5±5.5 kg/m2, respectively; there was no statistical difference in the comparison between the groups. Women with MS had a higher occurrence of tumors ≤2cm when compared to those without MS (49.2 vs. 31.8%, respectively) (p=0.038). Women with MS had a higher incidence of tumors with PR-positive (p=0.046), HER2-negative (p=0.038), when compared to women without MS (79.4 vs. 65.8% and 44.5 vs. 27.8%, respectively). In obese patients (BMI≥30 kg/m2), a higher proportion of HER2 negative tumors (p=0.047) was observed when compared to non-obese women (43.9 vs. 27.7%, respectively). In the multivariate analysis, a higher risk for tumors of the Luminal B HER-2 negative subtype was observed among women with MS (OR 2.00, 95%CI 1.03‒3.89), obese (OR 2.03, 95%CI 1.06‒3.90), and with central deposition of fat (OR 1.96, 95%CI 1.01‒4.03). Conclusion: Metabolic syndrome, obesity, and central fat deposition correlate with factors of good prognosis for breast cancer, such as tumors ≤2 cm, PR+ and HER2-, in postmenopausal women.

Gene polimorphisms and biological factors as possible predictors for patients with pleural metastatic breast cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10671-10671
Author(s):  
A. Montes-Worboys ◽  
A. Romero ◽  
A. M. Casas ◽  
E. Arellano ◽  
J. M. Juan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
High Frequency ◽  
Metastatic Cancer ◽  
Metastatic Breast ◽  
Control Group ◽  
Biological Factors ◽  
Talc Pleurodesis ◽  
Cancer Group ◽  
Increased Risk

10671 Background: Pronosis of breast cancer varies widely in patients with similar clinical features. Therefore, we investigated other factors with possible prognostic value. The CYP17 gene has a polimorphism related to a increased susceptibility to breast cancer (single T; A1 allele to C; A2 allele). ( Mitrunen et al. Cancer Epidemiol Biomarkers Prev 2000,9;12;1343–8). On the other hand, it has been found in the MTHFR gene a common C-T substitution at nucleotide 677 that is associated with reduced enzyme activity and increased risk of breast cancer (Capmbell et al., Breast Cancer Research 2002;4,6:R14). Other genes such as GSTT1 and GSTM1 variant genotypes have a controversial association to breast cancer. We have analyzed the genotype and biological factors in a group of patients with pleural metastatic cancer of the breast and compared it to a control group of women with no cancer. Methods: Forty-six patients with breast cancer and forty women as controls were includes in the study. Age at diagnosis of the primary tumor, TNM staging, interval free of disease, estrogen and progesteron receptors, Ki67, p53 and Her-2neu expression were recorded, as well as survival from the time of diagnosis and polimorphism of CYP17, MTHFR, GSTT1 and GSTM1 genes. Results: Mean survival differed significantly between patients having pleural effusion as the first site of relapse as compared to those with other sites of relapse (28’9 vs 11’9 months, p = 0’004). A high Ki67 expression correlated best with longer survival after talc pleurodesis. We detected a high frequency in the CYP17 A2 variant genotype in patients with metastatic breast cancer compared to the control group. As for MTFHR gene, we found a high frequency for the T/T genotypes variant in breast cancer group. No significant differences between control and cancer group were found in either GSTT1 and GSTM1 gene variations. Conclusions: Genotype and biological factors, such as factors investigated in this study, play an important role as predictors for patients with pleural metastatic breast cancer. No significant financial relationships to disclose.

The effect of aromatase inhibitors use on endothelial function among postmenopausal women with breast cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12064-e12064
Author(s):  
Ronny Maor ◽  
Elad Maor ◽  
Amanda Wanous ◽  
Sandhya Pruthi ◽  
Amir Lerman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Endothelial Function ◽  
Postmenopausal Women ◽  
Aromatase Inhibitors ◽  
Vascular Injury ◽  
Statistical Difference ◽  
Control Group ◽  
Increased Risk

e12064 Background: Data on long-term cardiovascular effects and safety of aromatase inhibitors (AI) are limited and conflicting. The purpose of the current study was to evaluate the effect of AI on vascular injury as assessed by peripheral endothelial function among women with breast cancer. Methods: This is an observational, prospective study of 96 postmenopausal women with breast cancer at initiation of treatment, with or without AI. All participants underwent baseline and 6-12 months follow up non-invasive peripheral endothelial function measurement. Reactive hyperemia index (RHI) was measured using the EndoPAT test. The primary endpoint was endothelial function deterioration of at least 20% between baseline and follow-up. Results: Mean age of the study population was 66±7 years. There was no statistical difference in demographic data between the groups. Compared with the control group, more women in the treatment group demonstrated worsening of RHI (53% vs. 42%, p = 0.207) between baseline and 6-12 month follow up measurement. There was no statistical difference between the groups at baseline. When RHI deterioration was evaluated as a dichotomous variable, with a 20% cutoff, women in the AI group demonstrated higher rates of RHI deterioration (28% vs. 8%, p=0.020). The risk of AIs for endothelial dysfunction was correlated with burden of cardiovascular (CV) risk, such that in women with >3 CV risk factors, AIs were associated with increased risk of RHI deterioration (42% vs. 10%, p=0.016), whereas in women with <2 CV risk factors, rates of RHI deterioration were similar in AI and control groups (20% vs. 7%, p = 0.232). Conclusions: This study suggests that AI therapy may be associated with vascular injury as detected by deterioration in endothelial function. The effect is more pronounced among women with higher baseline CV risk factor burden. The results of this study have potentially important implications for patients with breast cancer being treated with AI and for women at increased lifetime risk of breast cancer who may use AI for breast cancer risk reduction. Clinical trial information: NCT00719966.

scholarly journals Association of hyperlipidemia with breast cancer in Bangladeshi women

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Fatama Akter Chowdhury ◽  
Md Faridul Islam ◽  
Mahnaz Tabassum Prova ◽  
Mahbuba Khatun ◽  
Iffat Sharmin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Total Cholesterol ◽  
Benign Breast Disease ◽  
Density Lipoprotein ◽  
Breast Disease ◽  
Control Group ◽  
Lipid Levels ◽  
Healthy Women

Abstract Background The association of circulating lipids with breast cancer is being debated. The objective of this study was to examine the relationship between abnormal plasma lipids and breast cancer risk in Bangladeshi women. Methods This was a case-control study designed using a population of 150 women (50 women in each group). The lipid levels of women with breast cancer were compared to the lipid levels of women with benign breast disease (control group 1) and healthy women (control group 2). Study samples were collected from the Department of Surgery, Bangabandhu Sheikh Mujib Medical University, for a period of 1 year. Ethical measures were in compliance with the current Declaration of Helsinki. Statistical analysis was performed with SPSS version 26. Results All of the comparison groups shared similar sociodemographic, anthropometric and obstetric characteristics. The incidence of dyslipidemia was significantly higher in breast cancer patients (96%) than in healthy women (84%) and patients with benign breast disease (82%) (P < 0.05 for both). The levels of total cholesterol, triglycerides, and low-density lipoprotein (LDL) cholesterol among the breast cancer patient group were significantly higher than those among both benign breast disease patients and healthy women (P < 0.05), except for high-density lipoprotein (HDL) cholesterol. Adjusting for other factors, body mass index (BMI) (kg/m2) (> 23) [OR 53.65; 95% CI: 5.70–504.73; P < 0.001] and total cholesterol (mg/dl) (≥ 200) [OR 16.05; 95% CI: 3.13–82.29; P < 0.001] were independently associated with breast cancer. Conclusions Total cholesterol and BMI are independent predictors of breast cancer risk among Bangladeshi women.

Can patients with benign breast disease who are at high risk for breast cancer be identified using bombesin estimation?

1994 ◽  
Vol 1 (2) ◽  
pp. 37-41
Author(s):  
A Milewicz ◽  
J Daroszewski ◽  
J Jedrzejak ◽  
W Bielanski ◽  
D Jedrzejuk ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Benign Breast Disease ◽  
Absolute Risk ◽  
Subsequent Development ◽  
Breast Disease ◽  
Cystic Disease ◽  
Tissue Concentrations ◽  
Increased Risk ◽  
Risk Of Cancer

ABSTRACT Clinical follow-up studies of women with breast cystic disease indicate an increased risk of subsequent development of breast cancer, but the absolute risk marker has not yet been identified. It has been shown that bombesin/gastrin-releasing peptide can stimulate the proliferation of breast cancer cells in culture. In order to address the question of whether biological measurements might identify women with benign breast disease (BBD) at particular risk for breast cancer, analyses of bombesin and dehydroepiandrosterone sulfate (DHEAS) levels in tumor tissue from patients with breast cancer and BBD were carried out. The groups of patients comprised 13 women with breast cancer (mean age 52.3 years), 12 women with fibroadenoma (mean age 47.5 years), 6 with microcystic breast disease (mean age 43.5 years) and 6 with gross cystic breast disease (mean age 47.2 years). Malignant and benign tumor tissues were collected after mastectomy or tumorectomy. Bombesin and DHEA-S levels was measured by RIA after homogenization and extraction of tissues. Bombesin concentrations were higher in women with breast cancer (83.67±21.07 ng/g) than in other groups, except women with gross cystic disease (79.6±10.9 ng/g). In contrast, tissue concentrations of DHEAS in women with breast cancer (130.5±34.5 μg/g) were lower with comparison to the others, except women with fibroadenoma (177.7±84.9 μg/g). Bombesin and DHEAS tissue concentrations showed significant negative correlation only in women with fibroadenoma. All values are means±S.D. The significantly higher bombesin levels in tissues from women with breast cancer and in breast benign gross cystic disease (high risk of cancer) suggests the possible role of bombesin in the malignant process. Further studies are necessary to confirm these initial results.

HER-2/neu Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer

2000 ◽  
Vol 18 (2) ◽  
pp. 267-267 ◽  
Author(s):  
Azadeh Stark ◽  
Barbara S. Hulka ◽  
Scott Joens ◽  
Debra Novotny ◽  
Ann D. Thor ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Amplification ◽  
Benign Breast Disease ◽  
Statistical Significance ◽  
Breast Disease ◽  
Case Group ◽  
Increased Risk ◽  
Histopathologic Diagnosis ◽  
Ductal Hyperplasia ◽  
Her 2

PURPOSE: The purpose of this study was to determine whether the presence of HER-2/neu gene amplification and/or overexpression in benign breast disease was associated with an increased risk of subsequent breast cancer. PATIENTS AND METHODS: We conducted a nested case-control study of a cohort of women who were diagnosed with benign breast disease at the Mayo Clinic and who were subsequently observed for the development of breast cancer. Patients who developed breast cancer formed the case group, and a matched sample from the remaining cohort served as controls. Benign tissue samples from 137 cases and 156 controls and malignant tissues from 99 cases provided DNA or tissue for evaluation of HER-2/neu amplification and protein overexpression. RESULTS: Among the controls, seven benign tissues (4.5%) demonstrated low-level HER-2/neu amplification, whereas 13 benign (9.5%) and 18 malignant (18%) tissue specimens from cases exhibited amplification. HER-2/neu amplification in benign breast biopsies was associated with an increased risk of breast cancer (odds ratio [OR] = 2.2; 95% confidence interval [CI], 0.9 to 5.8); this association approached statistical significance. The risks for breast cancer associated with benign breast histopathologic diagnoses were OR = 1.1 (95% CI, 0.6 to 1.9) for lesions exhibiting proliferation without atypia and OR = 1.5 (95% CI, 0.4 to 5.6) for the diagnosis of atypical ductal hyperplasia. For women having both HER-2/neu amplification and a proliferative histopathologic diagnosis (either typical or atypical), the risk of breast cancer was more than seven-fold (OR = 7.2; 95% CI, 0.9 to 60.8). Overexpression of the HER-2/neu protein product, defined as membrane staining in 10% or more of epithelial cells, was found in 30% of the breast tumors but was not detected in any of the benign breast tissues. Case patients who had HER-2/neu gene amplification in their malignant tumor were more likely to have had HER-2/neu amplification in their prior benign biopsy (P = .06, Fisher’s exact test). CONCLUSION: Women with benign breast biopsies demonstrating both HER-2/neu amplification and a proliferative histopathologic diagnosis may be at substantially increased risk for subsequent breast cancer.

Sign in / Sign up

Export Citation Format

Share Document